Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Blood and lymphatic system disorders – page 47

  • 1 201 clinical trials
  • 458 recruiting
  • 364 conditions
  • 27 countries

Conditions in this area

364 conditions with trials, the busiest first

Plasma cell myeloma164Acute myeloid leukaemia132Chronic lymphocytic leukaemia77Myelodysplastic syndrome53Diffuse large B-cell lymphoma51Acute lymphocytic leukaemia43Follicular lymphoma41Plasma cell myeloma refractory41Mantle cell lymphoma32Myelofibrosis31Chronic myeloid leukaemia29B-cell small lymphocytic lymphoma28Immune thrombocytopenia27B-cell lymphoma25Factor VIII deficiency25Sickle cell disease25Hodgkin's disease23Non-Hodgkin's lymphoma22Haematological malignancy20Marginal zone lymphoma17B-cell lymphoma refractory16B-cell type acute leukaemia16Paroxysmal nocturnal haemoglobinuria16Diffuse large B-cell lymphoma refractory14+340

Clinical trials in Blood and lymphatic system disorders

1 201 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 201 clinical trials

Haematological malignancy+1

Not yet recruiting

Study on the Safety and Effectiveness of Pembrolizumab, Favezelimab, and Vibostolimab for Children and Young Adults with Blood Cancers or Solid Tumors

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years
  • Substances:Favezelimab
  • Sponsor:Merck Sharp & Dohme LLC

Lymphoma+1

Not yet recruiting

Study on Heparin Sodium and Sodium Chloride for Patients with Lymphoma or Myeloma Undergoing Stem Cell Collection

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Heparin Sodium
  • Sponsor:Karolinska University Hospital

Follicular lymphoma

Not yet recruiting

Study on Mosunetuzumab and Lenalidomide for Untreated Follicular Lymphoma Patients

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Mosunetuzumab
  • Sponsor:F. Hoffmann-La Roche AG

Acute lymphocytic leukaemia

Not yet recruiting

Study on the Safety and Feasibility of CART 19/22 T Cells and CART45RA-NKG2D Cells for Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:Cart 19/22 T Cells
  • Sponsor:Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Paz

Sickle cell anaemia

Not yet recruiting

Study on the Effectiveness and Safety of Exa-cel for Adolescents and Adults with Severe Sickle Cell Disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Busulfan
  • Sponsor:Vertex Pharmaceuticals Inc.

Acute myeloid leukaemia

Not yet recruiting

Study of Dasatinib for Patients with Acute Myeloid Leukemia Not Responding to Venetoclax-Azacitidine Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dasatinib
  • Sponsor:Institut Paoli-Calmettes

Plasma cell myeloma

Not yet recruiting

Study on Alnuctamab and Mezigdomide for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Alnuctamab
  • Sponsor:Celgene International II S.a.r.l.

Chronic lymphocytic leukaemia+1

Not yet recruiting

Study Comparing Nemtabrutinib, Ibrutinib, and Acalabrutinib for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Merck Sharp & Dohme LLC

Acute myeloid leukaemia

Not yet recruiting

Study on Treating Acute Myeloid Leukemia in Children and Adolescents Using CPX-351, Gemtuzumab Ozogamicin, and a Drug Combination

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Busulfan
  • Sponsor:GPOH gGmbH

Acute myeloid leukaemia+1

Not yet recruiting

Study on the Effectiveness and Safety of Imetelstat for Patients with High-Risk Myelodysplastic Syndromes or Acute Myeloid Leukemia After HMA Therapy Failure

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Hydrocortisone
  • Sponsor:Gcp-Service International West GmbH

Acute myeloid leukaemia

Not yet recruiting

Study on the Safety of Ivosidenib and Azacitidine for Adults with Newly Diagnosed IDH1m Acute Myeloid Leukemia Not Eligible for Intensive Chemotherapy

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Servier Affaires Medicales

Factor VIII deficiency+1

Not yet recruiting

Study on Joint Health in Hemophilia A and B Patients Using Efmoroctocog Alfa or Eftrenonacog Alfa

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Efmoroctocog Alfa
  • Sponsor:Swedish Orphan Biovitrum AB (publ)

Substances studied in this area

The therapies tested most often in Blood and lymphatic system disorders trials.

Dexamethasone139 clinical trialsRituximab122 clinical trialsVenetoclax114 clinical trialsCyclophosphamide100 clinical trialsLenalidomide98 clinical trialsCytarabine77 clinical trialsDaratumumab74 clinical trialsAzacitidine65 clinical trialsBortezomib64 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.